PL192280B1
(en)
*
|
1996-10-18 |
2006-09-29 |
Vertex Pharma |
Inhibitors of serinic proteases in particular that of hepatitis c virus ns3
|
US6608027B1
(en)
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
MXPA03000627A
(en)
*
|
2000-07-21 |
2004-07-30 |
Schering Corp |
Novel peptides as ns3-serine protease inhibitors of hepatitis c virus.
|
AR029851A1
(en)
*
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C
|
SV2003000617A
(en)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
|
KR20040077767A
(en)
*
|
2002-01-23 |
2004-09-06 |
쉐링 코포레이션 |
Proline compounds as NS3-serine protease inhibitors for use in treatment of hepatitis C virus infection
|
US7119072B2
(en)
|
2002-01-30 |
2006-10-10 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis C virus
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
EP1497282A2
(en)
*
|
2002-04-11 |
2005-01-19 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4 protease
|
KR20050048544A
(en)
|
2002-06-28 |
2005-05-24 |
이데닉스 (케이만) 리미티드 |
Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
|
WO2004026896A2
(en)
*
|
2002-09-23 |
2004-04-01 |
Medivir Ab |
Hcv ns-3 serine protease inhibitors
|
US20050075279A1
(en)
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
AU2011203054B2
(en)
*
|
2003-04-11 |
2012-04-26 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
|
EP1636208B1
(en)
*
|
2003-04-11 |
2012-02-29 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
MY143076A
(en)
|
2003-05-21 |
2011-02-28 |
Boehringer Ingelheim Int |
Hepatitis c inhibitors compounds
|
ES2726998T3
(en)
|
2003-05-30 |
2019-10-11 |
Gilead Pharmasset Llc |
Modified fluorinated nucleoside analogs
|
EP2368900A3
(en)
|
2003-07-18 |
2012-07-04 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
ES2351603T3
(en)
|
2003-07-25 |
2011-02-08 |
Idenix Pharmaceuticals, Inc. |
PURINE NUCLEOSID ANALOGS FOR THE TREATMENT OF DISEASES CAUSED BY FLAVIRIDAE INCLUDING HEPATITIS C.
|
WO2005021584A2
(en)
|
2003-08-26 |
2005-03-10 |
Schering Corporation |
Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
|
UY28500A1
(en)
*
|
2003-09-05 |
2005-04-29 |
Vertex Pharma |
INHIBITORS OF SERINE PROTEASES, IN PARTICULAR PROTEASA NS3-NS4A HCV.
|
AR045769A1
(en)
*
|
2003-09-18 |
2005-11-09 |
Vertex Pharma |
INHIBITORS OF SERINE PROTEASES, PARTICULARLY, THE HCV PROTEASE NS3-NS4A (VIRUS HEPATITIS C)
|
BRPI0414814A
(en)
|
2003-09-26 |
2006-11-14 |
Schering Corp |
macrocyclic hepatitis c virus serine ns3 protease inhibitors
|
EP2361925A1
(en)
|
2003-10-10 |
2011-08-31 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
EP1944042A1
(en)
|
2003-10-27 |
2008-07-16 |
Vertex Pharmceuticals Incorporated |
Combinations for HCV treatment
|
WO2005043118A2
(en)
|
2003-10-27 |
2005-05-12 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
US7253160B2
(en)
|
2003-11-20 |
2007-08-07 |
Schering Corporation |
Depeptidized inhibitors of hepatitis C virus NS3 protease
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
ES2358333T3
(en)
|
2004-01-21 |
2011-05-09 |
Boehringer Ingelheim International Gmbh |
MACROCYCLIC PEPTIDES WITH ACTION AGAINST THE VIRUS OF HEPATITIS C.
|
JP2008505849A
(en)
|
2004-02-04 |
2008-02-28 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Inhibitors of serine proteases, particularly HCV, NS3-NS4A protease
|
US20070049593A1
(en)
|
2004-02-24 |
2007-03-01 |
Japan Tobacco Inc. |
Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
|
PT1719773E
(en)
|
2004-02-24 |
2009-06-03 |
Japan Tobacco Inc |
Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor
|
JP2007525512A
(en)
|
2004-02-27 |
2007-09-06 |
シェーリング コーポレイション |
3,4- (Cyclopentyl) -condensed proline compounds as inhibitors of hepatitis C virus NS3 serine protease
|
US8067379B2
(en)
|
2004-02-27 |
2011-11-29 |
Schering Corporation |
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
|
JP2007525510A
(en)
|
2004-02-27 |
2007-09-06 |
シェーリング コーポレイション |
Compounds as inhibitors of hepatitis C virus NS3 serine protease
|
US7816326B2
(en)
|
2004-02-27 |
2010-10-19 |
Schering Corporation |
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
|
US7205330B2
(en)
|
2004-02-27 |
2007-04-17 |
Schering Corporation |
Inhibitors of hepatitis C virus NS3 protease
|
EP1737881B1
(en)
|
2004-02-27 |
2009-06-24 |
Schering Corporation |
Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
|
US7399749B2
(en)
|
2004-05-20 |
2008-07-15 |
Schering Corporation |
Substituted prolines as inhibitors of hepatitis C virus NS3 serine protease
|
EP2457895A1
(en)
*
|
2004-07-12 |
2012-05-30 |
Idun Pharmaceuticals, Inc. |
Tetrapeptide analogs
|
UY29016A1
(en)
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
ANALOGS OF INHIBITING DIPEPTIDES OF HEPATITIS C
|
EP1771454B1
(en)
|
2004-07-20 |
2011-06-15 |
Boehringer Ingelheim International GmbH |
Hepatitis c inhibitor peptide analogs
|
ATE513844T1
(en)
|
2004-08-27 |
2011-07-15 |
Schering Corp |
ACYLSULFONAMIDE COMPOUNDS AS INHIBITORS OF THE NS3 SERINE PROTEASE OF THE HEPATITIS C VIRUS
|
EP3109244B1
(en)
|
2004-09-14 |
2019-03-06 |
Gilead Pharmasset LLC |
Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
US7659263B2
(en)
|
2004-11-12 |
2010-02-09 |
Japan Tobacco Inc. |
Thienopyrrole compound and use thereof as HCV polymerase inhibitor
|
AR055198A1
(en)
*
|
2005-06-02 |
2007-08-08 |
Schering Corp |
PHARMACEUTICAL FORMULATIONS AND TREATMENT METHODS THAT USE THEM
|
US20070237818A1
(en)
*
|
2005-06-02 |
2007-10-11 |
Malcolm Bruce A |
Controlled-release formulation of HCV protease inhibitor and methods using the same
|
US20060276404A1
(en)
*
|
2005-06-02 |
2006-12-07 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
PL1891089T3
(en)
|
2005-06-02 |
2015-05-29 |
Merck Sharp & Dohme |
HCV protease inhibitors in combination with food
|
RU2415132C2
(en)
*
|
2005-06-16 |
2011-03-27 |
Новартис Аг |
Oxoazepanylacetamide and oxoazepanylphenoxyacetamide derivatives, compositions containing them and method for inhibiting hepatitis type c virus (hcv) replication
|
CN101242842A
(en)
|
2005-06-17 |
2008-08-13 |
诺瓦提斯公司 |
Use of SANGLIFEHRIN in HCV
|
US20110104109A1
(en)
*
|
2005-07-13 |
2011-05-05 |
Frank Bennett |
Tetracyclic indole derivatives and their use for treating or preventing viral infections
|
JP5230416B2
(en)
|
2005-07-29 |
2013-07-10 |
テイボテク・フアーマシユーチカルズ |
Macrocyclic inhibitor of hepatitis C virus
|
BRPI0614637A2
(en)
|
2005-07-29 |
2011-04-12 |
Tibotec Pharm Ltd |
macrocyclic hepatitis c virus inhibitors
|
EP1910341B1
(en)
*
|
2005-08-02 |
2013-01-02 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
US8399615B2
(en)
|
2005-08-19 |
2013-03-19 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates
|
NZ604087A
(en)
|
2005-08-19 |
2014-07-25 |
Vertex Pharma |
Processes and intermediates for the preparation of protease inhibitors
|
AR055395A1
(en)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
US7705138B2
(en)
|
2005-11-11 |
2010-04-27 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
JP5409008B2
(en)
|
2005-11-11 |
2014-02-05 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Hepatitis C virus variant
|
EP1966130B1
(en)
*
|
2005-12-23 |
2013-12-11 |
Zealand Pharma A/S |
Modified lysine-mimetic compounds
|
US7816348B2
(en)
|
2006-02-03 |
2010-10-19 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
US20070274951A1
(en)
*
|
2006-02-09 |
2007-11-29 |
Xiao Tong |
Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
|
EP2340836A1
(en)
|
2006-02-27 |
2011-07-06 |
Vertex Pharmceuticals Incorporated |
Co-crystals comprising VX-950 and their pharmaceutical compositions
|
CA2646229A1
(en)
|
2006-03-16 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Deuterated hepatitis c protease inhibitors
|
CA2647158C
(en)
*
|
2006-03-23 |
2012-07-31 |
Schering Corporation |
Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
|
WO2007133865A2
(en)
*
|
2006-04-11 |
2007-11-22 |
Novartis Ag |
Hcv/hiv inhibitors an their uses
|
US8017612B2
(en)
|
2006-04-18 |
2011-09-13 |
Japan Tobacco Inc. |
Piperazine compound and use thereof as a HCV polymerase inhibitor
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
CN101506167A
(en)
|
2006-08-17 |
2009-08-12 |
贝林格尔.英格海姆国际有限公司 |
Viral polymerase inhibitors
|
WO2008073282A2
(en)
*
|
2006-12-07 |
2008-06-19 |
Schering Corporation |
Ph sensitive matrix formulation
|
US20080188545A1
(en)
|
2006-12-21 |
2008-08-07 |
Alimardanov Asaf R |
Synthesis of pyrrolidine compounds
|
CN101631773A
(en)
|
2006-12-22 |
2010-01-20 |
先灵公司 |
4 of treatment or prevention HCV and related viral infections, the 5-ring annulated indole derivatives
|
JP5211068B2
(en)
*
|
2006-12-22 |
2013-06-12 |
メルク・シャープ・アンド・ドーム・コーポレーション |
4,5-cyclic indole derivatives for the treatment or prevention of HCV and related viral diseases
|
US8268803B2
(en)
|
2006-12-22 |
2012-09-18 |
Merck Sharp & Dohme Corp. |
5, 6-ring annulated indole derivatives and use thereof
|
AP2009004960A0
(en)
|
2007-02-27 |
2009-08-31 |
Vertex Pharma |
Co-crystals and pharmaceutical compositions comprising the same
|
CA2679426A1
(en)
|
2007-02-27 |
2008-09-04 |
Luc Farmer |
Inhibitors of serine proteases
|
ATE525068T1
(en)
|
2007-02-28 |
2011-10-15 |
Conatus Pharmaceuticals Inc |
METHOD FOR TREATING CHRONIC VIRAL HEPATITIS C USING RO 113-0830
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
CA2686051A1
(en)
|
2007-05-04 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Combination therapy for the treatment of hcv infection
|
WO2009018657A1
(en)
|
2007-08-03 |
2009-02-12 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
PE20090630A1
(en)
*
|
2007-08-29 |
2009-05-16 |
Schering Corp |
SUBSTITUTE INDEOL 2-CARBOXI DERIVATIVES AND METHODS FOR THEIR USE
|
TW200911807A
(en)
|
2007-08-29 |
2009-03-16 |
Schering Corp |
2,3-substituted azaindole derivatives and methods of use thereof
|
MX2010002319A
(en)
*
|
2007-08-29 |
2010-03-22 |
Schering Corp |
2, 3-substituted indole derivatives for treating viral infections.
|
JP5443360B2
(en)
|
2007-08-30 |
2014-03-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Co-crystal and pharmaceutical composition containing the same
|
US8383583B2
(en)
|
2007-10-26 |
2013-02-26 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
|
EP2222660B1
(en)
*
|
2007-11-16 |
2014-03-26 |
Merck Sharp & Dohme Corp. |
3-heterocyclic substituted indole derivatives and methods of use thereof
|
JP5416708B2
(en)
*
|
2007-11-16 |
2014-02-12 |
メルク・シャープ・アンド・ドーム・コーポレーション |
3-Aminosulfonyl-substituted indole derivatives and methods for their use
|
AU2008338273B2
(en)
|
2007-12-19 |
2014-10-02 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
US8309685B2
(en)
*
|
2007-12-21 |
2012-11-13 |
Celgene Avilomics Research, Inc. |
HCV protease inhibitors and uses thereof
|
US8293705B2
(en)
|
2007-12-21 |
2012-10-23 |
Avila Therapeutics, Inc. |
HCV protease inhibitors and uses thereof
|
TWI487522B
(en)
*
|
2007-12-21 |
2015-06-11 |
賽基艾維洛米斯研究股份有限公司 |
Hcv protease inhibitors and uses thereof
|
WO2009082697A1
(en)
*
|
2007-12-21 |
2009-07-02 |
Avila Therapeutics, Inc. |
Hcv protease inhibitors and uses thereof
|
ES2437147T3
(en)
|
2008-02-04 |
2014-01-09 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors
|
CA2719008A1
(en)
|
2008-03-20 |
2009-09-24 |
Enanta Pharmaceuticals, Inc. |
Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
AR072088A1
(en)
*
|
2008-06-13 |
2010-08-04 |
Schering Corp |
TRICYCLE INDOL DERIVATIVES AND THEIR METHODS OF USE
|
AU2009277172B2
(en)
|
2008-07-02 |
2014-05-29 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
AU2009282567B2
(en)
|
2008-08-20 |
2014-10-02 |
Merck Sharp & Dohme Corp. |
Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
TW201020245A
(en)
|
2008-08-20 |
2010-06-01 |
Schering Corp |
Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
CA2734489C
(en)
|
2008-08-20 |
2016-11-08 |
Southern Research Institute |
Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
AU2009282572B2
(en)
|
2008-08-20 |
2014-09-11 |
Merck Sharp & Dohme Corp. |
Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
TW201031675A
(en)
|
2008-12-23 |
2010-09-01 |
Pharmasset Inc |
Synthesis of purine nucleosides
|
CN102753563A
(en)
|
2008-12-23 |
2012-10-24 |
吉利德制药有限责任公司 |
Nucleoside analogs
|
NZ593648A
(en)
|
2008-12-23 |
2013-09-27 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
CA2750227A1
(en)
|
2009-01-07 |
2010-07-15 |
Scynexis, Inc. |
Cyclosporine derivative for use in the treatment of hcv and hiv infection
|
EP2403860B1
(en)
|
2009-03-04 |
2015-11-04 |
IDENIX Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
|
CA2758072A1
(en)
|
2009-04-08 |
2010-10-14 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
TWI576352B
(en)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
Nucleoside phosphoramidates
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
EP2435424B1
(en)
|
2009-05-29 |
2015-01-21 |
Merck Sharp & Dohme Corp. |
Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
|
TW201117812A
(en)
|
2009-08-05 |
2011-06-01 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
EP2503881B1
(en)
|
2009-11-25 |
2015-05-13 |
Merck Sharp & Dohme Corp. |
Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
|
US8362068B2
(en)
|
2009-12-18 |
2013-01-29 |
Idenix Pharmaceuticals, Inc. |
5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
|
US20130156731A1
(en)
|
2009-12-22 |
2013-06-20 |
Kevin X. Chen |
Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
|
EP2536410B1
(en)
|
2010-02-18 |
2015-09-23 |
Merck Sharp & Dohme Corp. |
Substituted pyrimidine derivatives and their use in treating viral infections
|
AU2011224698A1
(en)
|
2010-03-09 |
2012-11-01 |
Merck Sharp & Dohme Corp. |
Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases
|
CN102858790A
(en)
|
2010-03-31 |
2013-01-02 |
吉利德制药有限责任公司 |
Nucleoside Phosphoramidates
|
WO2011123586A1
(en)
|
2010-04-01 |
2011-10-06 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
AU2011286276A1
(en)
|
2010-07-26 |
2013-01-24 |
Merck Sharp & Dohme Corp. |
Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
|
CA2812779A1
(en)
|
2010-09-29 |
2012-04-19 |
Merck Sharp & Dohme Corp. |
Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
|
KR20130120481A
(en)
|
2010-10-08 |
2013-11-04 |
노파르티스 아게 |
Vitamin e formulations of sulfamide ns3 inhibitors
|
AU2011336632B2
(en)
|
2010-11-30 |
2015-09-03 |
Gilead Pharmasset Llc |
Compounds
|
AR085352A1
(en)
|
2011-02-10 |
2013-09-25 |
Idenix Pharmaceuticals Inc |
MACROCICLIC INHIBITORS OF SERINA PROTEASA, ITS PHARMACEUTICAL COMPOSITIONS AND ITS USE TO TREAT HCV INFECTIONS
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
US9243025B2
(en)
|
2011-03-31 |
2016-01-26 |
Idenix Pharmaceuticals, Llc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
US9156872B2
(en)
|
2011-04-13 |
2015-10-13 |
Merck Sharp & Dohme Corp. |
2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
US9061041B2
(en)
|
2011-04-13 |
2015-06-23 |
Merck Sharp & Dohme Corp. |
2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
WO2013033901A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
|
WO2013033900A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
|
WO2013033899A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
|
US9403863B2
(en)
|
2011-09-12 |
2016-08-02 |
Idenix Pharmaceuticals Llc |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
CA2847892A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
EP2755981A4
(en)
|
2011-09-14 |
2015-03-25 |
Merck Sharp & Dohme |
Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
|
EP2709613B2
(en)
|
2011-09-16 |
2020-08-12 |
Gilead Pharmasset LLC |
Methods for treating hcv
|
AR089650A1
(en)
|
2011-10-14 |
2014-09-10 |
Idenix Pharmaceuticals Inc |
PHOSPHATES 3,5-REPLACED CYCLES OF PURINE NUCLEOTIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
BR112014013224B1
(en)
|
2011-11-30 |
2023-03-07 |
Emory University |
ANTIVIRAL JAK INHIBITORS USEFUL IN THE TREATMENT OR PREVENTION OF RETROVIRAL AND OTHER VIRAL INFECTIONS
|
WO2013133927A1
(en)
|
2012-02-13 |
2013-09-12 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
|
EA201491511A1
(en)
*
|
2012-02-16 |
2014-12-30 |
АрКьюИкс ФАРМАСЬЮТИКАЛС, ИНК. |
LINEAR PEPTIDE ANTIBIOTICS
|
WO2013177195A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphate prodrugs for hcv infection
|
US9109001B2
(en)
|
2012-05-22 |
2015-08-18 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphoramidate prodrugs for HCV infection
|
WO2013177219A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
D-amino acid compounds for liver disease
|
AP2015008384A0
(en)
|
2012-10-08 |
2015-04-30 |
Univ Montpellier Ct Nat De La Rech Scient |
2'-Chloro nucleoside analogs for hcv infection
|
WO2014063019A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
WO2014078427A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of rp-nucleoside analog
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
US9211300B2
(en)
|
2012-12-19 |
2015-12-15 |
Idenix Pharmaceuticals Llc |
4′-fluoro nucleosides for the treatment of HCV
|
WO2014120981A1
(en)
|
2013-01-31 |
2014-08-07 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
US9309275B2
(en)
|
2013-03-04 |
2016-04-12 |
Idenix Pharmaceuticals Llc |
3′-deoxy nucleosides for the treatment of HCV
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
WO2014197578A1
(en)
|
2013-06-05 |
2014-12-11 |
Idenix Pharmaceuticals, Inc. |
1',4'-thio nucleosides for the treatment of hcv
|
US20150037282A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
NZ716840A
(en)
|
2013-08-27 |
2017-06-30 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
US10167298B2
(en)
|
2013-10-30 |
2019-01-01 |
Merck Sharp & Dohme Corp. |
Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
|
EP3063165A1
(en)
|
2013-11-01 |
2016-09-07 |
Idenix Pharmaceuticals LLC |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
WO2015081297A1
(en)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals, Inc. |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
EP3083654A1
(en)
|
2013-12-18 |
2016-10-26 |
Idenix Pharmaceuticals LLC |
4'-or nucleosides for the treatment of hcv
|
EP3113763A1
(en)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
US20170135990A1
(en)
|
2014-03-05 |
2017-05-18 |
Idenix Pharmaceuticals Llc |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
US10202411B2
(en)
|
2014-04-16 |
2019-02-12 |
Idenix Pharmaceuticals Llc |
3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
|
CN104293844B
(en)
*
|
2014-08-26 |
2017-10-10 |
苏州永健生物医药有限公司 |
A kind of synthetic method of Telaprevir intermediate
|
CA3025253A1
(en)
|
2016-06-21 |
2017-12-28 |
Orion Ophthalmology LLC |
Heterocyclic prolinamide derivatives
|
EP3472151A4
(en)
|
2016-06-21 |
2020-03-04 |
Orion Ophthalmology LLC |
Carbocyclic prolinamide derivatives
|
JP6989864B2
(en)
|
2017-05-05 |
2022-02-03 |
ジーランド ファーマ,アー/エス |
Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
|